MedTrace Logo

CAlgary SAlt for POTS

NCT05924646 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-07

No results posted yet for this study

Summary

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.

Conditions

  • Postural Orthostatic Tachycardia Syndrome

Interventions

DIETARY_SUPPLEMENT

Sodium Chloride Capsules

Table salt in slow release capsules.

OTHER

Microcystalline Cellulose Capsules

Microcrystalline Cellulose Capsules (Placebo)

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Satish R Raj · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05924646 on ClinicalTrials.gov